Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV

Background: People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVDs) and geriatric syndromes, including frailty. REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) demonstrated a 36% reduction in major adverse cardiovascular events (MACE) with pitav...

Full description

Bibliographic Details
Published in:JACC: Advances
Main Authors: Kristine M. Erlandson, MD, MS, Ariela R. Orkaby, MD, Triin Umbleja, MSc, Heather J. Ribaudo, PhD, Todd T. Brown, MD, PhD, Markella V. Zanni, MD, Marissa R. Diggs, AB, Sarah M. Chu, MSN, Kathleen V. Fitch, MSN, Carl J. Fichtenbaum, MD, Carlos Malvestutto, MD, MPH, Judith A. Aberg, MD, Gerald S. Bloomfield, MD, MPH, Judith S. Currier, MD, Karen T. Tashima, MD, Marcus Vinícius Guimarães de Lacerda, MD, PhD, Sonya L. Heath, MD, Michael T. Lu, MD, MPH, Alan Landay, PhD, George A. Kuchel, MD, Pamela S. Douglas, MD, Steven K. Grinspoon, MD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Subjects:
frailty
HIV
major adverse cardiovascular event
statin
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25005022

Internet

http://www.sciencedirect.com/science/article/pii/S2772963X25005022

Similar Items